GE Healthcare (NYSE: GE), a pioneer in digital mammography, today announced the introduction of an innovative technology to aid in breast cancer diagnosis. GE Healthcare‟s new SenoBright Contrast Enhanced Spectral Mammography (CESM) technology reduces ambiguity in mammography results, enabling physicians to detect and diagnose cancer with more confidence - even in the densest part of the breast tissue more rapidly and accurately.
Working like the multiple-flash, red-eye reduction function in a digital camera, SenoBright uses X-rays at multiple energies to create two separate exposures. These resulting images specifically illuminate and highlight areas where there is angiogenesis, growth of small blood vessels potentially related to the presence of cancer.
"A CESM exam takes from 5 to 10 minutes," said Dr. Clarisse Dromain, Gustave Roussy Cancer Institute, France. "During my investigation of the use of CESM with my own examinations of patients, I have been able to better define the spread of a cancer compared to standard mammography and ultrasound, and follow-up exams with an MRI (Magnetic Resonance Imaging) validated exactly the same results. Moreover, in the majority of cases the confidence in the diagnosis is high enough that the patient can be told the results that same day," she added.
The diagnostic challenge
SenoBright enables the digital mammography system to detect a whole new type of diagnostic information. Standard mammography only sees the structure of breast tissue. With SenoBright, doctors can also locate the proliferation of small blood vessels, potentially associated with cancerous tumor growth. In addition, it shows potential for measuring the extension of the lesion to help to plan surgery and treatment. Patients receive an intravenous injection of standard iodine contrast agent, and after two minutes undergo a five-minute digital mammography exam. CESM images are acquired in familiar mammography views so that that they can be quickly and easily correlated with standard results, facilitating interpretation by other specialists like surgeons or oncologists.
"Worldwide, more than 1.2 million people annually are diagnosed with breast cancer. Since 1965, GE Healthcare has made significant progress in providing solutions for breast cancer detection and diagnosis that really bring a change to people‟s lives. Today through „healthymagination‟, we continuously develop innovations to reduce costs, increase access and improve quality and efficiency of healthcare delivery around the globe," said Reinaldo Garcia, President and CEO of GE Healthcare for Europe, Middle East and Africa (EMEA). "GE Healthcare is pleased to bring to market such advanced breast imaging technologies like SenoBright, the result of over 10 years and $12 million investment of research and clinical collaborations. This innovative technology will support the earlier diagnosis of this prevalent disease, by providing access to new diagnostic information at a lower cost."
The product development was carried out in collaboration between GE Healthcare and Qatar Science & Technology Park (QSTP). The goal of the joint research program is to develop new and innovative technologies for aiding in the diagnosis of breast cancer using the latest developments in digital mammography. Page 2 of 3 Press Release - GE Healthcare – June 2010 GE Healthcare
Dr. Tidu Maini, Science and Technology Advisor to Her Highness, Sheikha Mozah bint Nasser Al Missned, and Executive Chairman of Qatar Science & Technology Park, said, "Our collaboration with GE Healthcare is a step towards making Qatar a global medical innovator while delivering real health benefits for the local community."
Same staff, same equipment— same day
SenoBright is an easy procedure that can be conducted by the same staff, using the same mammography equipment, potentially on the same day as the exam― allowing medical professionals to cut the critical time patients often have to wait from detection to diagnosis.
"Given our proven history of breast imaging innovations, GE is proud to release yet another innovative technology, soon to be available to much of our digital installed base. We are one of the only companies today to engineer and manufacture the entire mammography imaging chain from tube, and detector to review workstation, coupled with integration of the comprehensive local requirements for each customer, " said David Caumartin, GE Healthcare‟s General Manager Mammography. "SenoBright is likely to be a key enabler of accelerated patient workflow from diagnostics to treatment planning. It is enhancing the widely accepted technology of digital mammography by adding the functional information in order to detect angiogenesis."
Clarity of results
Digital mammography is considered a relevant means of breast cancer screening, delivering proven clinical outcomes. The sensitivity and specificity of images can, however, be affected by a range of factors. Dense breast tissue can overlap with lesions, which are not always visible on an X-ray, and radiologists‟ interpretation of images can vary.
Inconclusive digital mammography presents a range of challenges to healthcare professionals and patients. Ambiguity can result in diagnostic error, demanding further tests that can include ultrasound, invasive biopsy and Magnetic Resonance Imaging (MRI) scanning ― all of which could delay the diagnostic process, in some cases by weeks or even months.
SenoBright can remove this ambiguity, helping to ensure that those patients who need to go into cancer treatment do so ― and do so quickly. Whereas patients who do not have malignant lesions have the potential to find out on the same day, relieving their burden of uncertainty. Compared to mammography alone, clinical studies show that SenoBright improves sensitivity and specificity:
• for every 100 cancers, there is the potential to find 13 more.
• 6 more benign lesions out of 100 can be correctly classified.
• 19 more patients out of 100 without cancer can be sent home.
"The addition of intravenous contrast to mammography gives us the possibility to obtain information in the mammogram that was previously only obtained from MRI," said Dr. David Dershaw, Director of Breast Imaging at Memorial Sloan-Kettering Cancer Center, USA. "This has the potential to convey the advantages of MRI imaging in screening and diagnosis to women for whom this test is indicated but not currently available."
The new CESM technology works with an upgrade to GE Healthcare Senographe DS and Senographe Essential digital mammography equipment. GE‟ Senographe platforms are full-field digital mammography systems designed to meet clinical needs, from screening to diagnostic and interventional procedures and designed for future advanced applications.
About GE Healthcare
GE Healthcare (gehealthcare.com) provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $16 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries.
For our latest news, please visit newsroom.gehealthcare.com/.
The SenoBright option cannot be put into service until it has been made to comply with CE marking. It may not be available in all regions. The SenoBright option is not cleared or approved by U.S. FDA.